{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T14:51:05Z","timestamp":1786632665792,"version":"build-2736575974"},"reference-count":23,"publisher":"American Diabetes Association","issue":"2","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":12,"URL":"https:\/\/www.diabetesjournals.org\/journals\/pages\/license"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL180694"],"award-info":[{"award-number":["R01HL180694"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3,1]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>Use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) for diabetes or weight management may affect pregnancy outcomes. We sought to estimate the number of U.S. women of reproductive age eligible for GLP-1 RA therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                    <jats:p>Using 2017\u20132023 nationally representative survey data, we identified nonpregnant U.S. women aged 18\u201344 years who met trial-based eligibility criteria for diabetes, weight management, or secondary cardiovascular prevention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Among 3,218 participants, 1,447 were eligible for GLP-1 RAs, representing 24.6 million U.S. women. Among GLP-1 RA\u2013eligible women, mean BMI was 34.8 kg\/m2, 8.3% had diabetes, and 1.9% had prior cardiovascular disease. Eligibility was primarily for weight management (24.1 million), followed by diabetes (2.0 million) and cardiovascular prevention (0.34 million).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>Nearly half of U.S. reproductive-age women are eligible for GLP-1 RAs. Given limited pregnancy safety data and rising cardiometabolic burden in reproductive-age women, research is needed to guide counseling and coverage of preconception GLP-1 RA use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title\/>\n                  <\/jats:sec>","DOI":"10.2337\/doc25-0040","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T19:07:53Z","timestamp":1773428873000},"page":"198-202","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":0,"title":["GLP-1 RA Eligibility in Reproductive-Age U.S. Women"],"prefix":"10.2337","volume":"1","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-5888-5464","authenticated-orcid":false,"given":"Ivy","family":"Shi","sequence":"first","affiliation":[{"name":"Richard A. and Susan F. Smith Center for Outcomes Research, Beth Israel Deaconess Medical Center 1 , Boston, MA"},{"name":"Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School 2 , Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0643-1859","authenticated-orcid":false,"given":"Sadiya S.","family":"Khan","sequence":"additional","affiliation":[{"name":"Department of Medicine and Preventive Medicine, Feinberg School of Medicine, Northwestern University 3 , Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Grobman","sequence":"additional","affiliation":[{"name":"Division of General Obstetrics and Gynecology, Brown University 4 , Providence, RI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9510-2979","authenticated-orcid":false,"given":"Dhruv S.","family":"Kazi","sequence":"additional","affiliation":[{"name":"Richard A. and Susan F. Smith Center for Outcomes Research, Beth Israel Deaconess Medical Center 1 , Boston, MA"},{"name":"Division of Cardiology, Beth Israel Deaconess Medical Center and Harvard Medical School 5 , Boston, MA"},{"name":"Department of Epidemiology, Harvard T.H. Chan School of Public Health 6 , Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"key":"2026081310114692100_B1","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1001\/jama.2023.2307","article-title":"Cardiovascular risk factor prevalence, treatment, and control in US adults aged 20 to 44 years, 2009 to March 2020","volume":"329","author":"Aggarwal","year":"2023","journal-title":"JAMA"},{"key":"2026081310114692100_B2","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1161\/CIR.0000000000001258","article-title":"Forecasting the economic burden of cardiovascular disease and stroke in the United States through 2050: a presidential advisory from the American Heart Association","volume":"150","author":"Kazi","year":"2024","journal-title":"Circulation"},{"key":"2026081310114692100_B3","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1001\/jamacardio.2024.4657","article-title":"Semaglutide eligibility across all current indications for US adults","volume":"10","author":"Shi","year":"2025","journal-title":"JAMA Cardiol"},{"key":"2026081310114692100_B4","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1161\/CIRCULATIONAHA.124.070766","article-title":"Treating reproductive-aged women with glucagon-like peptide-1 receptor agonists: what are the clinical considerations?","volume":"150","author":"Sharma","year":"2024","journal-title":"Circulation"},{"key":"2026081310114692100_B5","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1001\/jamacardio.2025.0637","article-title":"Periconceptional glucagon-like peptide-1 receptor agonist use and discontinuation","volume":"10","author":"Khan","year":"2025","journal-title":"JAMA Cardiol"},{"key":"2026081310114692100_B6","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1001\/jamainternmed.2023.6663","article-title":"Safety of GLP-1 receptor agonists and other second-line antidiabetics in early pregnancy","volume":"184","author":"Cesta","year":"2024","journal-title":"JAMA Intern Med"},{"key":"2026081310114692100_B7","unstructured":"National Center for Health Statistics. National Health and Nutrition Examination Survey, 2017\u20132020 and 2021\u20132023. Accessed 1 October 2024. Available from https:\/\/wwwn.cdc.gov\/nchs\/nhanes\/Default.aspx"},{"key":"2026081310114692100_B8","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"2026081310114692100_B9","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"2026081310114692100_B10","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet"},{"key":"2026081310114692100_B11","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/jama.2021.1831","article-title":"Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial","volume":"325","author":"Wadden","year":"2021","journal-title":"JAMA"},{"key":"2026081310114692100_B12","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA"},{"key":"2026081310114692100_B13","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.diabet.2018.12.001","article-title":"Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: insights from the SUSTAIN 1-7 trials","volume":"45","author":"Aroda","year":"2019","journal-title":"Diabetes Metab"},{"key":"2026081310114692100_B14","unstructured":"National Center for Health Statistics. National Health and Nutrition Examination Survey: Analytic Guidelines, 2011\u20132014 and 2015\u20132016. 14 December 2018. Accessed 1 October 2024. Available from https:\/\/wwwn.cdc.gov\/nchs\/data\/nhanes\/analyticguidelines\/11-16-analytic-guidelines.pdf"},{"key":"2026081310114692100_B15","unstructured":"National Center for Health Statistics. National Health and Nutrition Examination Surgery, 2017\u2013March 2020 Prepandemic File: Sample Design, Estimation, and Analytic Guidelines. May 2022. Accessed 1 October 2024. Available fromhttps:\/\/www.cdc.gov\/nchs\/data\/series\/sr_02\/sr02-190.pdf"},{"key":"2026081310114692100_B16","article-title":"survey: Analysis of complex survey samples","author":"Lumley"},{"key":"2026081310114692100_B17","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1161\/CIR.0000000000001124","article-title":"Optimizing prepregnancy cardiovascular health to improve outcomes in pregnant and postpartum individuals and offspring: a scientific statement from the American Heart Association","volume":"147","author":"Khan","year":"2023","journal-title":"Circulation"},{"key":"2026081310114692100_B18","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s13669-023-00356-9","article-title":"Preventing adverse cardiovascular outcomes in pregnancy complicated by obesity","volume":"12","author":"Purohit","year":"2023","journal-title":"Curr Obstet Gynecol Rep"},{"key":"2026081310114692100_B19","doi-asserted-by":"crossref","first-page":"e2413172","DOI":"10.1001\/jamanetworkopen.2024.13172","article-title":"GLP-1 receptor agonist discontinuation among patients with obesity and\/or type 2 diabetes","volume":"7","author":"Do","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2026081310114692100_B20","first-page":"8","article-title":"Poll: roughly 12% of US adults have used a GLP-1 drug, even if unaffordable","volume":"332","author":"Harris","year":"2024","journal-title":"JAMA"},{"key":"2026081310114692100_B21","doi-asserted-by":"crossref","DOI":"10.57264\/cer-2025-0083","article-title":"Affordable Access to GLP-1 Obesity Medications: Strategies to Guide Market Action and Policy Solutions","author":"Pearson","year":"2025"},{"key":"2026081310114692100_B22","doi-asserted-by":"crossref","first-page":"r2361","DOI":"10.1136\/bmj.r2361","article-title":"Trump strikes deal with Ozempic and Mounjaro makers to cut prices of obesity injections","volume":"391","author":"Brown","year":"2025","journal-title":"BMJ"},{"key":"2026081310114692100_B23","unstructured":"Palmer\n              K\n            \n          . How invisible medical groups are powering telehealth\u2019s GLP-1 \u2018gold rush\u2019. STAT10. 17 October2024. Accessed October 2024. Available from https:\/\/www. statnews.com\/2024\/10\/17\/telehealth-online-compounded-glp1-prescriptions-medical-groups\/"}],"container-title":["Diabetes Obesity and Cardiometabolic CARE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/docm-care\/article-pdf\/1\/2\/198\/859165\/docm250040.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/docm-care\/article-pdf\/1\/2\/198\/859165\/docm250040.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T14:11:57Z","timestamp":1786630317000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/docm-care\/article\/1\/2\/198\/164598\/GLP-1-RA-Eligibility-in-Reproductive-Age-U-S-Women"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,1]]},"references-count":23,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,3,13]]},"published-print":{"date-parts":[[2026,3,1]]}},"URL":"https:\/\/doi.org\/10.2337\/doc25-0040","relation":{},"ISSN":["3067-3518","3067-3534"],"issn-type":[{"value":"3067-3518","type":"print"},{"value":"3067-3534","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,1]]}}}